By GottaLaff
Now, thankfully, there's been a reversal... during that very special Friday night news quiet time. Shhhh, don't tell anyone, but it was all just a big, silly, sit-com style misunderstanding:
Caught between a pivotal industry ally and the protests of Congressional Democrats, the Obama administration on Friday backed away from what drug industry lobbyists had said this week was a firm White House promise to exclude from a proposed health care overhaul the possibility of allowing the government to negotiate lower drug prices under Medicare.Good for the Dems. More like this, please.The reversal underscored the delicate balancing act the White House has pursued in its strategy of negotiating behind-the-scenes deals to win industry support without alienating liberal supporters on Capitol Hill.
Pressed by drug industry lobbyists, a White House deputy chief of staff, Jim Messina, confirmed in an e-mail message on Wednesday that the White House shared the drug lobbyists’ interpretation of the deal: that any health care overhaul would not include allowing direct government negotiation of drug prices or require certain additional price rebates. Since Wednesday, other representatives of the White House had also stood by Mr. Messina’s statement as well.
After reading reports about Mr. Messina’s e-mail message, House and Senate Democrats loudly protested that they would not be bound by any such agreement to remove clauses allowing government negotiation of drug prices under Medicare — something Democrats have sought for years.
Several Senate Democrats said Friday that, in a private meeting, White House officials had told them there was no such deal, sowing yet more confusion. House Democratic leaders vowed to fight against it.
Then, after contending for two days that the Senate Democrats had misunderstood the White House aide’s comments, the White House appeared Friday night to back away.
In a telephone interview, Linda Douglass, a White House spokeswoman on health matters, said the question of government drug-price bargaining “was not discussed during the negotiations.” Asked if that meant such a provision was excluded, as the top drug lobbyists had previously said, Ms. Douglass declined to comment, repeating, “It was not discussed.”
White House officials said Friday that Mr. Messina, the deputy chief of staff who sent the e-mail message, had not intended to confirm that the deal ruled out price negotiations. [...]
[T]he drug industry lobby appeared to line up once again with the White House, perhaps satisfied that the White House had at least ruled out the price rebates in the House bill. [...]
The full terms of the White House agreement with the drug makers, like a similar deal with the hospital industry, have never been disclosed. [...]
As Mr. Tauzin spoke up, the White House initially chose not to argue. But faced with a chorus of Congressional complaints, the administration appears to have recalibrated its position.